01578nas a2200217   4500008004100000245004600041210004500087260001300132300001200145490000700157520098600164653001701150653003201167653001401199653001801213100003001231700001901261700002101280700002301301856003601324       2021                        eng d00aInotropes in Chronic Beta-Blocker Therapy0 aInotropes in Chronic BetaBlocker Therapy  cMay 2021  a828-8340 v133 a<p class="rtejustify">The increasing rate of cardiovascular disorders contributes to rising hospitalized patients receive chronic oral beta-blocker therapy. Beta-blockers remain one of the fundamental therapy for chronic heart failure. Still, their role in decompensated heart failure and severe sepsis during hospitalization is often debated and inconsistent in clinical practice. In recent years, evidence of the efficacy and clinical outcomes of beta-blockers in acute heart failure (AHF) have accumulated. Clinical research indicates that chronic beta-blockade withdrawals should be prevented, or as soon as hemodynamic stabilization and euvolemic condition are reached, it should be reinstituted. As a subset of AHF patients with low cardiac output required inotropes, the choice of proper agent is fundamental. Different inotropic agents such as inhibitors of the phosphodiesterase, levosimendan, and dobutamine also their associations with beta-blockers are discussed.</p>
10aBeta-blocker10aDecompensated heart failure10aInotropes10aSevere sepsis1 aAlsagaff, Mochamad, Yusuf1 aSusanti, Melly1 aThaha, Mochammad1 aJonatan, Christian  uhttps://phcogj.com/article/1431